InflaRx

Missed target failed trial trial failure
Pharma

InflaRx scraps vilobelimab study in rare skin disorder

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to the drawing board.
Fraiser Kansteiner May 28, 2025 9:55am
FDA

FDA authorizes InflaRx's anti-inflammation drug for severe COVID

Apr 4, 2023 5:12pm